Pharmaceutical News

RSS

UMMS' iHeal project uses emerging technologies to detect drug cravings and intervene

Clinical researchers at the University of Massachusetts Medical School (UMMS) are combining an innovative constellation of technologies such as artificial intelligence, smartphone programming, biosensors and wireless connectivity to develop a device designed to detect physiological stressors associated with drug cravings and respond with user-tailored behavioral interventions that prevent substance use.

22 Feb 2012

FDA approves APP's preservative-free Methotrexate Injection

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market preservative-free Methotrexate Injection, USP. APP currently manufactures Methotrexate Injection with preservative.

22 Feb 2012

Russian government's censorship of websites with harm reduction methods for drug users helps fuel HIV epidemic, IPS reports

"A recent government crackdown on Russian media, particularly online information portals specializing in health tips and harm reduction methods for drug users, has sparked widespread public opposition, with critics claiming that the 'draconian silencing' of public health advocates could worsen an already perilous health situation in the country," Inter Press Service reports.

22 Feb 2012

BioLineRx BL-7010 may reduce gluten toxicity in patients with celiac disease

BioLineRx, a biopharmaceutical development company, announced the publication of pre-clinical results demonstrating that BL-7010, an orally available treatment for celiac disease, reduces gluten toxicity (the negative effect of gluten on the patient's body).

22 Feb 2012

New chemical compound to treat brain damage from stroke

Researchers at the University of Copenhagen have designed, produced and patented a new chemical compound for the possible treatment of brain damage caused by stroke. The compound binds 1,000 times more effectively to the target protein in the brain than the potential drug currently being tested on stroke victims.

22 Feb 2012

Promising antibiotic alternative to fight bacteria that causes strep throat

Researchers have discovered a promising alternative to common antibiotics used to fight the bacteria that causes strep throat. In an article published in the Proceedings of the National Academy of Sciences, the scientists discussed how their discovery could fight the infection with a reduced risk of antibiotic resistance.

22 Feb 2012

EMA grants positive scientific opinion for Pyramax to treat malaria

Pyramax-, a fixed-dose combination of pyronaridine and artesunate, becomes the first antimalarial to be granted a positive scientific opinion from the European Medicines Agency (EMA) under Article 58. This once daily, 3-day treatment is indicated for acute, uncomplicated Plasmodium falciparum and blood-stage Plasmodium vivax malaria in adults and children over 20 kg.

22 Feb 2012

Weight gain or loss may also depend on medicines taken

Weight gain or loss may not always be caused by what you eat or how much you exercise. For some, it's the medicines you're taking.

22 Feb 2012

FDA grants orphan-drug designation to Arno's AR-42 for treatment of meningioma, schwannoma

Arno Therapeutics, Inc. announced today that its investigational compound, AR-42, has been granted orphan-drug designation by the U.S. Food and Drug Administration for the treatment of meningioma and schwannoma of the central nervous system.

21 Feb 2012

FDA to review rejected weight loss drug Qnexa

The weight loss pill Qnexa has been once rejected by the FDA over safety concerns. But this Wednesday it will get a second chance before an FDA advisory committee. Qnexa maker Vivus Inc. hopes something might come out of this second chance. The company will be submitting new safety data from patients who took Qnexa for a second year after completing a one-year clinical trial.

21 Feb 2012

Drug 'addicted' newborn the latest hysteria driven absurdity

The Florida Society of Pain Management Providers (www.Flspmp.org) feels it is vital to set the factual record straight in light of the mass deception used to foment a hysteria driven war on pain medications that now is threatening the health and welfare of Florida's chronic pain patients.

21 Feb 2012

AWMSG makes prostate cancer drug abiraterone available on the NHS

Cancer Research UK welcomes the news that the All Wales Medicines Strategy Group (AWMSG) has made prostate cancer drug abiraterone available on the NHS, paving the way for NICE to make a positive ruling when they publish their final guidance in May.

21 Feb 2012

Some answers about prescription psychiatric drugs

The circumstances of Whitney Houston's demise have dominated headlines and search trends since news outlets first reported of her death. Her struggle with addiction was covered extensively by the media, and even discussed candidly by Houston herself during several high-profile interviews.

20 Feb 2012

KI's chemical interaction map shows how inhibitors bind to PARP enzymes

A team of researchers at Karolinska Institutet in Sweden has generated a map over the effects of small drug-like molecules on PARP1 and other similar proteins in the body. This map may explain the mechanism behind putative side effects of the so-called PARP inhibitors, and can play an important role in the development of novel tailor-made cancer drugs.

20 Feb 2012

FDA to review inhaled caffeine device - AeroShot

The U.S. Food and Drug Administration (FDA) has announced its intentions of investigating whether inhalable caffeine sold in lipstick-sized canisters called AeroShot is safe for consumers and if its manufacturer was right to brand it as a dietary supplement.

20 Feb 2012

Massive infant Tylenol recall

Johnson & Johnson has announced the recall of its entire U.S. supply of infants' Tylenol—about 574,000 bottles—due to a design flaw. The flaw involved bottles of grape-flavoured infants' Tylenol, which had only just returned to shelves in November announced J&J last Friday.

20 Feb 2012

Natural compound of Chilean avocado plant can combat resistant yellow staphylococci

Aggressive infections in hospitals are an increasing health problem worldwide. The development of bacterial resistance is alarming. Now a young Danish scientist has found a natural substance in a Chilean rainforest plant that effectively supports the effect of traditional treatment with antibiotics.

20 Feb 2012

EC approves Plexxikon's Zelboraf to treat BRAF mutation-positive MM

Plexxikon Inc., a member of Daiichi Sankyo Group, today announced that the European Commission has approved Zelboraf (vemurafenib) for the monotherapy treatment of adult patients with BRAFV600 mutation-positive unresectable or metastatic melanoma.

20 Feb 2012

Modified imatinib cancer drug prevents morphine tolerance in rats

By reformulating the common cancer drug imatinib (Gleevec), researchers have eliminated morphine tolerance in rats - an important step toward improving the effectiveness of chronic pain management in patients, according to researchers at The University of Texas MD Anderson Cancer Center.

20 Feb 2012

Study reveals potential strength of different anti-HIV combination drugs

Using a mathematical formula that carefully measures the degree to which HIV infection of immune system cells is stalled by antiretroviral therapy, AIDS experts at Johns Hopkins have calculated precisely how well dozens of such anti-HIV drugs work, alone or in any of 857 likely combinations, in suppressing the virus. Results of the team's latest research reveal how some combinations work better than others at impeding viral replication, and keeping the disease in check.

19 Feb 2012